26 registrations that name NAC as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 26 registrations
Status
Phase
8US sites across 6 states
1
2 to 4
5 to 19
20 or more
All 26 registrations
RecruitingNCT05123365
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
Phase 1 and 2
University of California, Irvine
About 27 people
Started Jan 3, 2022
In plain words A Phase 1 and 2 study of NAC in people 18 and older, run by University of California, Irvine. It plans to enroll about 27 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Myeloproliferative Neoplasm; MPN; Essential Thrombocythemia; Polycythemia Vera; Myelofibrosis.
≥18 years of age
Have a diagnosis of essential thrombocythemia (ET), polycythemia vera (PV), or myelofibrosis (MF) according to the 2016 WHO criteria
Has not taken interferon-alpha or a JAK inhibitor (such as ruxolitinib or fedratinib) for treatment of MPN in the past 28 days before enrollment.
May continue on current MPN treatment, including aspirin, hydroxyurea, or anagrelide. Therapeutic phlebotomies should continue per the patient's usual regimen.
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
N-Acetylcysteine
Registered summary
This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).
Where, as registered
2 US sites in 1 state.
RecruitingNCT07464886
Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth
Phase 3
University of Cincinnati
About 160 people
Started Feb 26, 2026
In plain words A Phase 3 study of NAC in people 15 to 24, run by University of Cincinnati. It plans to enroll about 160 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 15 to 24. Conditions: Mild Depression.
age between 15 years, 0 months to 24 years, 11 months old;
presenting with mild depression, defined by meeting DSM-5 criteria for a current major depressive episode, mild severity, or persistent depressive disorder, or other specified depressive disorder (depressive episode with insufficient…
medication-naïve or medication free for at least 5 half-lives since the last use of a psychoactive medication, with the exception of stimulants for ADHD;
if on ADHD stimulant medication over 2 months prior to screening, willing to maintain stimulant dose constant during the study participation;
1 more inclusion criterion and the exclusion criteria are on the listing.
The primary goal is to investigate to what extent changes in glutamate and glutathione modulation and functional integration between brain networks associated with emotion and attention regulation are associated with treatment response in mildly depressed youth.
Where, as registered
1 US site in 1 state.
RecruitingNCT07049952
BabySTrong II taVNS Feeding Trial
Phase 2 and 3
Medical University of South Carolina
About 88 people
Started Nov 16, 2025
In plain words A Phase 2 and 3 study of NAC in people 39 weeks to 54 weeks, run by Medical University of South Carolina. It plans to enroll about 88 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 39 weeks to 54 weeks. Conditions: Feeding Delays; Neonates and Term Infants.
infants >39 weeks PMA making minimal progress in oral feeds
trying to learn feeding for at least 2wks if beginning feeds at term (>37wks PMA), and 4wks if beginning feeds <36wks PMA,
may po every feed without volume limitations by therapists
The exclusion criteria are on the listing.
What it tests, as registered
taVNS; NAC and taVNS; inactive taVNS; sterile water and inactive taVNS
Registered summary
The long-term goal of this project is to develop a therapy to assist pre-term and term infants with brain injury overcome difficulties in learning to feed so that infants may be discharged home with their families and avoid the burdens of of a gastrostomy tube (G-tube) or prolonged home nasogastric feeding. Few other therapies exist for infants who are not making progress with feeding volumes at term age. To tackle this problem, we took the novel approach of pairing non-invasive nerve stimulation of the vagus nerve at the ear (taVNS) stimulation with the motor skills of feeding. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT03652753
Pilon Fracture With Intra-articular Injection of N-Acetylcysteine (Pilon NAC)
Phase 4
University of Missouri-Columbia
About 30 people
Started Jan 1, 2019
In plain words A Phase 4 study of NAC in people 18 and older, run by University of Missouri-Columbia. It plans to enroll about 30 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Pilon Fracture.
Closed high energy pilon fracture requiring a staged procedure
The exclusion criteria are on the listing.
What it tests, as registered
N-acetylcysteine; Saline
Registered summary
High energy intra-articular fractures of the distal tibia, or Pilon fracture, is a devastating injury with multiple short and long term complications. The incidence of these injuries is increasing as survival rates after motor vehicle collisions increase. The current standard of care for high energy pilon fractures is to place an external fixator at the time of injury and then provide definitive internal fixation when the soft tissue envelope allows, which is usually around 10-14 days. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT04278898
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Single-dose
Phase 2
Stanford University
About 24 people
Started Feb 12, 2021
In plain words A Phase 2 study of NAC in people 3 to 12, run by Stanford University. It plans to enroll about 24 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 3 to 12. Conditions: Autism Spectrum Disorder.
children between 3 years and 12 years 11 months at the time of consent
diagnosis of Autism Spectrum Disorder confirmed with the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule-2 (ADOS-2), or Brief Observation of Symptoms of Autism (BOSA), or Childhood Autism Rating…
at least moderate Restricted and Repetitive Behaviors severity defined by a Children's Yale-Brown Obsessive Compulsive Scale for children with autism spectrum disorder score ≥ 11,
physical development indicative of prepubescence as defined by the criteria for Tanner Stage 1,
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
N-Acetylcysteine
Registered summary
The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC.
Where, as registered
1 US site in 1 state.
RecruitingNCT05241262
Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels
Phase 1
Michio Hirano, MD
About 18 people
Started Jul 6, 2023
In plain words A Phase 1 study of NAC in people 18 to 80, run by Michio Hirano, MD. It plans to enroll about 18 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Mitochondrial Disease.
Ages 18-80 years
Low brain glutathione (GSH) levels as determined by magnetic resonance spectroscopic imaging (MRSI)
Individuals who carry, or are suspected of carrying the m.3243A>G mitochondrial mutation (genetic confirmation of mutation required prior to initiation of NAC)
The exclusion criteria are on the listing.
What it tests, as registered
N-Acetylcysteine
Registered summary
N-Acetylcysteine (NAC), an anti-oxidant, will be studied to investigate the effects on brain glutathione levels, cognitive skills, motor skills, and quality of life. A group of 18 participants will take either 1800, 3600 or 5400 mg per day of N-acetylcysteine (NAC) for 3 months in this dose escalation study. The investigators want to determine first if the 3600 mg dose per day is safe and might provide some efficacy. If the 3600 mg dose is safe, then additional participants will be treated with 5400 mg per day of NAC, for up to a total of 18 participants. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06956482
PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis
Phase 3
University Hospital, Lille
About 477 people
Started May 22, 2026
In plain words A Phase 3 study of NAC in people 18 to 75, run by University Hospital, Lille. It plans to enroll about 477 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Alcoholic Hepatitis.
Patients aged 18-75
Alcohol consumption of more than 40g/day (women) and 50g/day (men)
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
N-Acetylcysteine (NAC) Treatment; Prednisolone; Placebo of N-acetylcysteine; Placebo of Prednisolone 10mg; Prednisolone 10mg
Registered summary
Only patients suffering from a severe form of alcoholic hepatitis (Maddrey's discriminant function greater than 32) require medical treatment. Oral prednisolone for 28 days is the only treatment which has been proven to improve short-term survival over placebo in patients with severe alcoholic hepatitis. However, prednisolone alone cannot be regarded as an ideal treatment because some patients still have a bad outcome despite being treated with corticosteroids. Response to treatment can be predicted by the Lille score, a simple tool that is calculated after 7 days of prednisolone course. The full summary is on the listing.
Where, as registered
No US site; France (1).
RecruitingNCT07273071
Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-Acetylcysteine
Phase 4
Theis S. Itenov
About 360 people
Started Sep 7, 2026
In plain words A Phase 4 study of NAC in people 18 and older, run by Theis S. Itenov. It plans to enroll about 360 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Sepsis; Acute Infection; Severe Infection.
Age ≥18 years
Documented clinical suspicion of infection
Model for end-stage liver disease (MELD) score ≥9
The exclusion criteria are on the listing.
What it tests, as registered
N-Acetylcysteine (NAC) Treatment
Registered summary
The primary objective of the IMPACT-NAC trial is to assess the effects of N-acetylcysteine on survival and hospital length of stay in adults admitted to the emergency department with acute infection or sepsis and evidence of liver dysfunction. The main question it aims to answer is: does N-acetylcysteine increase the number of days alive and out of the hospital within the first 14 days after enrolment in the trial? To answer this question, we will conduct a randomized, double-blinded controlled trial of 360 participants. The full summary is on the listing.
Where, as registered
No US site; Denmark (1).
RecruitingNCT05509153
A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers
Phase 2
Western Sydney Local Health District
About 160 people
Started Jun 1, 2024
In plain words A Phase 2 study of NAC in people 18 and older, run by Western Sydney Local Health District. It plans to enroll about 160 people at 5 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Huntington Disease.
Able to provide informed consent
Huntingtin gene expansion carrier with >= 39 CAG repeats
Absence of unequivocal motor signs of HD - that is, UHDRS
Diagnostic Confidence Level needs to be <4 upon enrolment
8 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
NAC; Placebo
Registered summary
NAC-preHD is a phase II randomized placebo controlled study of oral NAC among premanifest HD gene expansion carriers, with clinical and radiological outcome at three years.
Where, as registered
No US site; Australia (5).
RecruitingNCT06377410
Efficacy & Safety of Dry Powder Ivy Extract (Syrup Prospan) Versus NAC Among COPD Patients
No phase
National University of Malaysia
About 100 people
Started May 1, 2024
In plain words A study of NAC in people 40 and older, run by National University of Malaysia. It plans to enroll about 100 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 40 and older. Conditions: Chronic Obstructive Pulmonary Disease.
Participants with documented post bronchodilator FEV1/FVC < 70 or <LLN
Age 40 years and above
Able to perform spirometry
Participant with Stable COPD based on GOLD 2023 strategy
The exclusion criteria are on the listing.
What it tests, as registered
Syrup Prospan; N-Acetylcysteine
Registered summary
As the third global leading cause of death, Chronic Obstructive Pulmonary Disease (COPD) affects more than 300 million people worldwide. These patients suffer from 0.5-3.5 exacerbations per year on average. Each exacerbations dampened their health status as well as quality of life, not to mention a great burden to our healthcare system. Those partially treated or prolonged exacerbations would subsequently lead to unfavorable disease progression. Hence a holistic approach in managing each exacerbations is very crucial. The full summary is on the listing.
Where, as registered
No US site; Malaysia (2).
RecruitingNCT05142735
Effects of NAC on Symptoms of CHR Patients
No phase
Centre for Addiction and Mental Health
About 90 people
Started Jan 13, 2023
In plain words A study of NAC in people 16 to 35, run by Centre for Addiction and Mental Health. It plans to enroll about 90 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 16 to 35. Conditions: Prodromal Schizophrenia.
meeting Criteria of Psychosis-Risk Syndromes (COPS) criteria on the Structured Interview for Psychosis-Risk Syndromes (SIPS)
capacity to provide informed consent
if female, participant is not of child-bearing potential, defined as females who have undergone a sterilization procedure or have been post-menopausal for at least 1 year prior to screening OR participant is of child-bearing potential and…
The exclusion criteria are on the listing.
What it tests, as registered
N-Acetylcysteine; Placebo
Registered summary
Schizophrenia is a chronic debilitating psychotic disorder. Identifying persons with "clinical high-risk" (CHR) symptoms, which are like those of schizophrenia but less severe, and providing psychiatric care to these individuals has been shown to help prevent psychosis. Current medications used for CHR symptoms, however, are associated with substantial side effect burden. Therefore, practice guidelines do not recommend current medications as routine treatment for the CHR state, and there is a need to identify new treatments for this condition. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
RecruitingNCT07414212
Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS)
Phase 1 and 2
Biogipuzkoa Health Research Institute
About 90 people
Started Nov 25, 2025
In plain words A Phase 1 and 2 study of NAC in people 18 to 75, run by Biogipuzkoa Health Research Institute. It plans to enroll about 90 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Amyotrophic Lateral Sclerosis.
Patients diagnosed with ALS according to the Gold Coast criteria;
Disease duration ≤ 18 months;
Men and women aged 18 to 75 years;
Total ALSFRS-R score ≥ 30 for all 12 categories;
10 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Acetylcysteine; EH301; Riluzole
Registered summary
This study is designed to evaluate whether a combination of N-acetylcysteine (NAC) and EH-301 can slow down or improve symptoms of amyotrophic lateral sclerosis (ALS). Researchers will assess changes in disease progression using the ALS Functional Rating Scale-Revised (ALSFRS-R), a standard tool for measuring daily functioning in people with ALS. The main question is whether taking NAC together with EH-301 can prevent symptom worsening and possibly improve existing ALS symptoms. The full summary is on the listing.
Where, as registered
No US site; Spain (1).
RecruitingNCT04693949
Effect of Nano-structured Alumina Coating on the Bond Strength of Zirconia Resin-bonded Fixed Dental Prostheses
No phase
University of Ljubljana, Faculty of Medicine
About 80 people
Started Jan 3, 2018
In plain words A study of NAC in people of any age, run by University of Ljubljana, Faculty of Medicine. It plans to enroll about 80 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people of any age; healthy volunteers accepted. Conditions: Missing Incisors; Zirconia Surface Pretreatment; Children; Adults; Debonding.
What it tests, as registered
NAC; APA
Registered summary
The purpose of this study is to evaluate the clinical outcome of resin-bonded fixed dental prostheses (RBFDPs) pretreated with nanostructured alumina coating (NAC). The study adopts a prospective, randomized, controlled, double-blind design contrasting the use of NAC to air-borne particle abrasion (APA) (control) as a surface pretreatment method of zirconia RBFDPs used for replacing missing central or lateral incisors. The primary outcome evaluated is the retention/survival of the zirconia RBFDPs pretreated with APA and NAC.
Where, as registered
No US site; Slovenia (1).
RecruitingNCT07117630
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
Phase 2
Fudan University
About 60 people
Started Sep 25, 2025
In plain words A Phase 2 study of NAC in female participants 18 and older, run by Fudan University. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 and older. Conditions: Breast Cancer.
Women aged ≥ 18 years old.
Patients with histologically confirmed HR+/HER2- invasive breast cancer (specific definition: ER > 10% tumor cell positivity by immunohistochemistry is defined as ER positive, PR positive, PR > 10% tumor cell positivity is defined as PR…
Patients with HR+/HER2- advanced breast cancer who have experienced disease progression after receiving systemic therapy including CDK4/6 inhibitors and endocrine therapy.
Patients whom the investigator judges to be suitable for continued endocrine therapy
8 more inclusion criteria and the exclusion criteria are on the listing.
This is a prospective, Phase II, open-label, two-arm parallel study evaluating the efficacy and safety of combined treatment (L-Ornithine L-Aspartate, N-Acetylcysteine) with CDK4/6 inhibitors and Fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer (ABC) who have progressed on prior standard therapy including CDK4/6 inhibitors and endocrine therapy.
Where, as registered
No US site; China (1).
RecruitingNCT06367413
Effects of Protein and NAC Co-ingestion on Skeletal Muscle Recovery
No phase
University of Thessaly
About 30 people
Started Apr 8, 2024
In plain words A study of NAC in male participants 18 to 27, run by University of Thessaly. It plans to enroll about 30 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 to 27; healthy volunteers accepted. Conditions: Aseptic Muscle Injury.
Free of asthma, kidney disease, bleeding disorders, peptic ulcers.
Free of musculoskeletal injuries and limitations.
Abstain from dietary energy restriction.
Do not use medication such as anti-inflammatory drugs, antibiotics, antihypertensive drugs or anticoagulants.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Placebo; NAC; NAC + Whey Protein
Registered summary
Previous evidence suggests that though N-acetylcysteine (NAC) supplementation following eccentric exercise-induced muscle damage disrupts the skeletal muscle's repair and remodelling process at 8 days of recovery, it attenuates substantially the decline of skeletal muscle performance during the first 48 hours of recovery. The enhanced performance capacity during the first phase of recovery in response to NAC supplementation might be attributed to the altered redox status in skeletal muscle as a consequence of the NAC-mediated elevation of reduced glutathione (GSH) levels. The full summary is on the listing.
Where, as registered
No US site; Greece (1).
Not yet recruitingNCT07227649
NAC-REPAIR for Post-surgical Pain
Phase 2
University of Arizona
About 80 people
Starts Oct 15, 2026 (estimated)
In plain words A Phase 2 study of NAC in people 18 to 75, run by University of Arizona. It plans to enroll about 80 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Carpal Tunnel Surgery; Trigger Finger Disorder; De Quervain Syndrome; Guyon's Canal; Dupuytren Contracture; Morton Neuroma; Tarsal Tunnel Syndrome; Plantar Fasciopathy; Peroneal Nerve Entrapment.
Elective outpatient hand/upper-extremity or foot/ankle surgery (single site; same-day discharge)
Baseline visit feasible ≤14 days pre-op
Can complete surveys/blood draw
Provides informed consent
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
NAC; NAC 0mg/day (Placebo)
Registered summary
This pilot asks whether peri-operative N-acetylcysteine (NAC) improves recovery after common outpatient hand/foot-ankle surgery-specifically, does NAC reduce pain and opioid use and enhance function by modulating redox-inflammatory pathways? Primary objectives are to establish feasibility (accrual, adherence, follow-up), estimate NAC vs placebo effects on pain, function, and opioid consumption, and characterize inflammatory signatures that may predict response. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07543458
Therapeutics for Moderate and Severe Dengue
Phase 3
Oxford University Clinical Research Unit, Vietnam
About 8,800 people
Starts Oct 1, 2026 (estimated)
In plain words A Phase 3 study of NAC in people 5 and older, run by Oxford University Clinical Research Unit, Vietnam. It plans to enroll about 8,800 people at 18 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 5 and older. Conditions: Dengue; Severe Dengue; Mosquito-Borne Diseases; Vector Borne Diseases; Arbovirus Infections; Flavivirus Infections; RNA Virus Infections; Hemorrhagic Fever.
Age ≥5 years
Decision to hospitalise
Clinical diagnosis of dengue
Participants must also have at least one of the following:
12 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Placebo; Dexamethasone; N-Acetylcysteine; Standard of care; Baricitinib
Registered summary
The purpose of this multi-site, factorial randomised, platform trial is to evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection. Our primary aim is to find safe and affordable therapeutics which prevent disease progression among those at high risk for severe dengue, and improve outcomes for those with established severe disease, thereby also reducing the substantial burden placed on health systems in dengue endemic regions.
Where, as registered
No US site; Bangladesh (3), Colombia (3), Malaysia (2), Nepal (2), Thailand (2), Vietnam (2), Brazil (1), Indonesia (1), Peru (1), Philippines (1).
Not yet recruitingNCT07136987
A Trial of 2 Disease-Modifying Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Function Recovery
Phase 3
Open Source Pharma Foundation
About 1,104 people
Starts Jan 2026 (estimated)
In plain words A Phase 3 study of NAC in people 18 to 65, run by Open Source Pharma Foundation. It plans to enroll about 1,104 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Tuberculosis.
Willing and able to provide signed written consent (or, in the case of illiteracy, witnessed oral consent plus patient thumbprint) prior to undertaking any trial-related procedures.
Body weight (in light clothing without shoes) between 30 and 90 kg.
Radiographic evidence of pulmonary tuberculosis
Positive Xpert TB/RIF (original or Ultra) for MTB
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Metformin; N-Acetylcysteine (NAC) Treatment; Standard TB treatment
Registered summary
Tuberculosis is a leading global cause of morbidity and mortality. Even if cured, a majority patients are left with bronchiectasis and fibrosis, permanent conditions that impair lung function. Large cohort studies have confirmed that even modest loss of lung function is associated with excess mortality risk. This study will examine if two treatments, metformin and N-acetylcysteine (NAC), can promote the recovery of lung function in TB if given together with standard TB treatment. There currently are no drugs approved for this indication.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07869342
NAC for Hematopoietic Recovery in Low/Intermediate-Risk AML After CR: A Randomized Controlled Study
No phase
Peking University People's Hospital
About 180 people
Starts Oct 2026 (estimated)
In plain words A study of NAC in people 18 to 65, run by Peking University People's Hospital. It plans to enroll about 180 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Acute Myeloid Leukemia, Adult.
Low-risk or intermediate-risk AML per the 2022 European Leukemia Net (ELN) genetic risk stratification guidelines
Aged 18 to 65 years (inclusive)
Induction chemotherapy with the HAA regimen. For patients diagnosed with AML harboring FLT3-ITD mutation, treatment with the HAA regimen combined with the FLT3 inhibitor Sorafenib is permitted.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
N-acetyl-L-cysteine (NAC)
Registered summary
This prospective, single-center, randomized controlled clinical trial aims to evaluate whether N-acetyl-L-cysteine (NAC) can promote hematopoietic recovery after chemotherapy in patients with acute myeloid leukemia (AML), and to explore its effects on disease remission and bone marrow microenvironment. Eligible participants are newly diagnosed low- or intermediate-risk AML patients aged 18-65 years, with no severe organ dysfunction or active infection. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07737262
Prophylactic NAC to Improve Platelet Engraftment After Haploidentical Transplantation in Severe Aplastic Anemia Patients
Phase 3
Peking University People's Hospital
About 142 people
Starts Sep 30, 2026 (estimated)
In plain words A Phase 3 study of NAC in people 14 to 50, run by Peking University People's Hospital. It plans to enroll about 142 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 14 to 50. Conditions: Aplastic Anemia.
Diagnosed with aplastic anemia and scheduled to receive first haplo-HSCT
Aged 14 to 50 years
Hematopoietic Cell Transplant Comorbidity Index (HCT-CI) ≤ 2
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
N-acetylcysteine
Registered summary
This study aims to evaluate the efficacy and safety of prophylactic oral N-acetylcysteine (NAC) for facilitating platelet engraftment in patients with severe aplastic anemia (SAA) receiving haploidentical hematopoietic stem cell transplantation (haplo-HSCT). This is a prospective, multicenter, randomized controlled trial enrolling a total of 142 patients with SAA scheduled for their first haplo-HSCT, who will be randomly assigned at a 1:1 ratio to the NAC prophylaxis group or the control group, with 71 subjects in each arm. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07290530
24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
Phase 3
Nacuity Pharmaceuticals, Inc.
About 80 people
Starts Dec 2026 (estimated)
In plain words A Phase 3 study of NAC in people 18 and older, run by Nacuity Pharmaceuticals, Inc.. It plans to enroll about 80 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Retinitis Pigmentosa (RP); Usher Syndrome.
Able to comprehend and willing to sign an informed consent form (ICF) and to adhere to the study protocol.
Diagnosed with Usher syndrome.
EZ zone width ≥ 500 microns, which includes the fovea in each eye at Visit 1 (Screening).
All edges of the EZ area in both eyes can be visualized at Visit 1 (Screening).
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
N-acetylcysteine amide; Placebo
Registered summary
The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001. The main questions it aims to answer are: Does NPI-001 slow down the loss of photoreceptors? What medical problems do participants have when taking NPI-001? Researchers will compare NPI-001 to a placebo (a look-alike substance that contains no drug) to see if NPI-001 works to preserve vision. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07156786
N-Acetylcysteine Roles in Preserving Renal Function Measured by Urinary KIM-1 (Kidney Injury Molecule-1) and Serum Creatinine on Cancer Patients With Cisplatin Based Chemotherapy: A Randomized Placebo-Controlled Trial
Phase 2 and 3
Fakultas Kedokteran Universitas Indonesia
About 72 people
Starts Sep 15, 2025 (estimated)
In plain words A Phase 2 and 3 study of NAC in people 18 and older, run by Fakultas Kedokteran Universitas Indonesia. It plans to enroll about 72 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Kidney Function Issue; Acute Kidney Injury; Cancer (Solid Tumors); Kidney Function Tests; Acetylcysteine Adverse Reaction.
Patient with cancer/ malignancy proven by histopathological examination
Patient with GFR ≥60 ml/mins/1,73 m²
Patient with normal complete blood count and liver function test result
Patient with good performance status (Karnofsky score ≥80)
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
N-acetylcysteine (NAC); Placebo
Registered summary
The goal of this clinical trial is to learn if N-Acetylcysteine drug works to protect kidney function in adults patient with cancer. Kidney function will be measured by laboratory parameter using urine sample (KIM-1 urine) and blood sample (serum creatinine). The main questions it aims to answer are: 1. Does N-Acetylcysteine lower the level of KIM-1 (Kidney Injury Molecule) in patients urine indicating kidney function protection? 2. Does N-Acetylcysteine lower the level of creatinine in patients blood indicating kidney function protection? Participants will: 1. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07803952
N-Acetylcysteine in the Management of Spontaneous Bacterial Peritonitis
Phase 1 and 2
Tanta University
About 60 people
Starts Sep 10, 2026 (estimated)
In plain words A Phase 1 and 2 study of NAC in people 18 to 65, run by Tanta University. It plans to enroll about 60 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: SBP - Spontaneous Bacterial Peritonitis.
What it tests, as registered
Placebo; NAC
Registered summary
Spontaneous bacterial peritonitis (SBP) is one of the most serious infectious complications of liver cirrhosis and ascites. It affects approximately 10-30% of hospitalized patients with decompensated cirrhosis and carries an in-hospital mortality of 20-40% despite appropriate antimicrobial therapy. SBP results from bacterial translocation across the intestinal mucosa together with cirrhosis-associated immune dysfunction, leading to impaired bacterial clearance and exaggerated systemic inflammation. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT06890507
The Anti-Anginal Effects of N-Acetylcysteine (NAC) in Patients with Angina and Non-Obstructive Coronary Arteries (ANOCA)
Phase 2
University of Adelaide
About 25 people
Starts Jun 1, 2025 (estimated)
In plain words A Phase 2 study of NAC in female participants 18 and older, run by University of Adelaide. It plans to enroll about 25 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 and older. Conditions: Angina Attacks; Non Obstructive Coronary Artery Disease.
Provision of informed consent prior to any study specific procedures
Female patients aged ≥18 years
No obstructive CAD (defined as either absence of epicardial lesions with ≥50% luminal narrowing in any coronary artery segment on coronary angiography or normal findings on computed tomography (CT) angiogram, indicating the absence of…
Chest pain occurring ≥3 times/week in the preceding two weeks.
The exclusion criteria are on the listing.
What it tests, as registered
N-Acetylcysteine (NAC); Placebo
Registered summary
The goal of this clinical trial is to determine if N-acetylcysteine (NAC) can reduce angina frequency in women with Angina with Non-Obstructive Coronary Arteries (ANOCA). It will also assess the impact of NAC on health status and quality of life. The full summary is on the listing.
Where, as registered
No US site; Australia (1).
Not yet recruitingNCT06546475
A Pilot Trial of Tapering Antipsychotics for Patients in Remitted Psychosis Co-administering With N-Acetylcysteine
Phase 4
National Taiwan University Hospital
About 20 people
Starts Aug 1, 2024 (estimated)
In plain words A Phase 4 study of NAC in people 18 to 60, run by National Taiwan University Hospital. It plans to enroll about 20 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60. Conditions: Psychosis.
Both male and female outpatients or patients at psychiatric daycare service
Age 18-60 years old at the time of screening
A diagnosis of schizophrenia, schizophreniform disorder, psychosis NOS, based on the DSM-5 criteria
With a Positive and Negative Syndrome Scale (PANSS), score < 3 in all 3 positive symptoms (P1: delusion, P2: conceptual disorganization, P3: hallucination) and 2 general symptoms (G9: unusual thought, G5: mannerism and posturing) for at…
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
N-Acetylcysteine
Registered summary
The investigators are going to observe if add-on of n-acetylcysteine (NAC) 1200 or 2400 mg/d during tapering of antipsychotics in patients with remitted psychosis can help to reduce the pre-requisite of stabilization to 3 months (compared to the 6 months prerequisite of a previous Guided Antipsychotic Reduction to Minimum Effective Dose (GARMED) trial,) smoothly, without increased risk of relapse or frequency of adverse events compared to the 2-year results of the GARMED trial
Where, as registered
No sites listed yet.
Not yet recruitingNCT06260566
Tolerability of Enteral NAC in Infants
Phase 1
Sanjiv Harpavat
About 12 people
Starts Oct 2026 (estimated)
In plain words A Phase 1 study of NAC in people 122 days to 273 days, run by Sanjiv Harpavat. It plans to enroll about 12 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 122 days to 273 days. Conditions: Biliary Atresia.
122-273 days of life at time of enrollment
Confirmed diagnosis of biliary atresia based on intraoperative cholangiogram
Able to tolerate oral nutrition and medications and not on continuous tube feeds
Anticipated inpatient admission of at least 4 days
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
N-Acetylcysteine
Registered summary
Biliary atresia (BA) is a neonatal liver disease characterized by impaired bile flow and is the most common indication for pediatric liver transplantation. BA can be treated with the Kasai portoenterostomy (KP), a procedure that attempts to restore bile flow and slow disease progression. However, success of the KP procedure is quite variable, and lack of adjuvant medical therapies following KP is a major gap in pediatric hepatology. This study begins to explore oral N-acetylcysteine (NAC) as a potential medical therapy in BA by determining whether an oral formulation can be given to infants. The full summary is on the listing.